An interventional study of CereVasc eShunt System and VP Shunt in Normal Pressure Hydrocephalus, sponsored by CereVasc Inc. Active, not recruiting at 32 sites in 3 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by CereVasc Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hydrocephalus, Normal Pressure with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Hydrocephalus, Normal Pressure · United States.
Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 23rd registered.
78 studies on the registry are indexed under Hydrocephalus, Normal Pressure; 20 are open to participants now.
Browse Hydrocephalus, Normal Pressure studies →4 of the 24 studies in Hydrocephalus, Normal Pressure with a site in United States are open now. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 60–99
University of South Florida · Sites in United States
Ages 40+
University of South Florida · Sites in United States
Ages 40+
Johns Hopkins Bloomberg School of Public Health · Sites in United States
Ages 65+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Hydrocephalus, Normal Pressure studies recruiting now, 12 (75%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is above the median of 49 across 40 interventional studies indexed under Hydrocephalus, Normal Pressure.
Median enrollment 30 across the 15 interventional studies, 20 across the 9 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
CereVasc Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
CereVasc Inc has 3 studies filed under Hydrocephalus, Normal Pressure — fewer than ten, so there is no comparison to draw.
4 of the studies in Hydrocephalus, Normal Pressure with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04011566University of South FloridaAssessment of ShuntCheck Performance Characteristics in Asymptomatic Patients With Normal Pressure Hydrocephalus | 2026-11 |
| NCT06498960CereVasc IncEvaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus | 2027-01 |
| NCT04309487University of South FloridaDiagnostic Accuracy of ShuntCheck Compared to Radionuclide Shunt: Patency in Patients With Normal Pressure Hydrocephalus | 2027-01 |
| NCT06426004Johns Hopkins Bloomberg School of Public HealthAddressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Hydrocephalus, Normal Pressure with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
The STRIDE study is a prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each subject must meet the following criteria:
Clinical presentation consistent with NPH including two or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with all of the following:
Exclusion Criteria:
Each subject may not:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Endovascular placement of the eShunt Implant
Device: CereVasc eShunt System
Surgical ventriculo-peritoneal shunt procedure
Device: VP Shunt
The eShunt System consists of the following components: * eShunt Implant * eShunt Delivery Catheter and Transfer Tool * eShunt Anchor
Also known as: eShunt System, eShunt Implant
Control arm - VP shunt
Primary Effectiveness Endpoint
The Primary Effectiveness Endpoint of this study is change in gait impairment at 6-months, compared to baseline. Change in gait impairment is defined as reduction in time required to complete the Timed Up and Go (TUG) test (stand up, walk 3m, turnaround, walk 3m, sit down).
Time frame: 6 months
Primary Safety Endpoint
All adverse events will be reported for the investigational (eShunt System) and control (VP shunt) arms. Safety will be analyzed based on a review of all AEs in the investigational arm compared to the control arm, through 6-months post-procedure to demonstrate an acceptable safety profile of the eShunt System.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.
Of 21 interventional studies with no phase under Hydrocephalus, Normal Pressure, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hydrocephalus, Normal Pressure →
CereVasc Inc